mRNA Vaccines for Animals Market to Expand Rapidly with 61.1% CAGR by 2031 | Ceva Animal Health, Merck Animal Health, Areterna

Los Angeles, United States - QY Research has released a new publication titled "Global mRNA Vaccines for Animals Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031." This comprehensive study provides an in-depth evaluation of the worldwide mRNA Vaccines for Animals industry, uncovering the major forces influencing market growth and delivering high-value insights for investors, industry leaders, and strategic decision-makers. The report examines critical elements such as market dynamics, evolving technologies, segmentation trends, regional developments, and the competitive landscape. With data backed by rigorous research and expert interpretation, it offers an authoritative guide to understanding the macroeconomic and microeconomic factors reshaping the global market.

The global market for mRNA Vaccines for Animals was estimated to be worth US$ 81.02 million in 2024 and is forecast to a readjusted size of US$ 2513 million by 2031 with a CAGR of 61.1% during the forecast period 2025-2031.

Download FREE Sample PDF (Including Full TOC, Tables & Charts): https://qyresearch.in/request-sample/pharma-healthcare-mrna-vaccines-for-animals-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

Market Overview -

The study provides verified historical data and forward-looking projections, offering readers a clear understanding of how the mRNA Vaccines for Animals market is expected to expand through 2031. Using accurate and validated data sources, the report answers key questions related to market size, growth patterns, strategic initiatives, and future investment potential.

mRNA vaccines for animals are a type of veterinary vaccine that use messenger RNA (mRNA) technology to stimulate an immune response against specific pathogens in livestock, pets, and other animals. These vaccines work by delivering synthetic mRNA encoding viral or bacterial antigens into the animal's cells, prompting the immune system to recognize and fight the targeted disease. Compared to traditional vaccines, mRNA vaccines offer faster development timelines, improved efficacy, and the ability to rapidly adapt to emerging animal diseases. They are being explored for various applications, including livestock diseases (such as foot-and-mouth disease), zoonotic infections, and companion animal health.

Market Drivers, Challenges & Restraints -

This section outlines the various elements influencing the trajectory of the mRNA Vaccines for Animals market:

Market Development Opportunities & Main Driving Factors -

mRNA vaccines for animals, as a new generation of biological products, are reshaping the global veterinary vaccine landscape with their rapid development, high specificity, and scalability. According to annual reports from animal health companies and brokerage research, the demand for epidemic prevention in the livestock industry continues to rise, particularly against transboundary infectious diseases and major animal epidemics, which accelerates investment in novel vaccines. The proven success of mRNA technology in human COVID-19 vaccines validates its potential in veterinary applications. Coupled with strong policy support for food safety, livestock modernization, and public health, the market expansion potential for animal mRNA vaccines is significant.

Market Challenges, Risks, & Restraints -

Despite promising prospects, animal mRNA vaccines face multiple challenges. Their storage, transportation, and mass production require stringent cold chain and advanced equipment, leading to higher costs compared to traditional vaccines. Regulatory frameworks remain immature, with varying standards for registration and safety validation across regions, adding uncertainty to commercialization. Additionally, the industry is dominated by multinational animal health giants with strong technological and financial advantages, creating barriers for smaller firms facing fierce competition and potential technological hurdles.

Downstream Demand Trends -

As livestock farming becomes increasingly large-scale and intensive, and as consumer awareness of food safety and animal health grows, demand for safe and effective novel vaccines continues to rise. In particular, poultry, swine, and companion animal sectors exhibit strong demand for rapid-response vaccines against emerging diseases. Growing government investment in animal disease prevention and farmers' need to reduce losses and improve efficiency will further drive adoption. In the long term, animal mRNA vaccines are poised to become a critical technology supporting livestock stability and food supply security.

Major Company Included: -

Ceva Animal Health
Merck Animal Health
Areterna
Bayer
BioNTech
Genvax Technologies
BioVenic
Moderna
Ruipu Biotechnology
Jinyu Bio-technology
Shanghai Shen Lian Biomedical
Suzhou Kerui Meide Biomedical Technology
Shanghai Rnacure Biopharma

The competitive section of the report provides essential insights needed for companies to strengthen their market positioning. It highlights the strategies adopted by leading players-covering innovation, pricing models, marketing channels, distribution networks, and regional expansion. This evaluation enables market participants to identify competitive advantages and understand challenges that may affect their long-term performance.

Market Segmentation -

The report presents a granular breakdown of the global mRNA Vaccines for Animals market, emphasizing CAGR, market share, future potential, and emerging trends across each segment.

By Type

Non-replicating mRNA vaccines
Self-replicating mRNA vaccines

By Application

Pigs
Poultry
Companion Animals
Ruminants

This segmentation helps identify high-growth niches and valuable investment opportunities across product types and applications.

Regional Analysis -

The report offers a detailed geographic assessment covering four major regions and key contributing countries. Insights include consumption patterns, production levels, market share distribution, and long-term growth prospects.

North America

United States
Canada
Mexico

Latin America

Brazil
Other key regional markets

Asia-Pacific

China
Japan
India
South Korea
ASEAN Countries

Europe, Middle East & Africa (EMEA)

Germany
France
United Kingdom
GCC Countries
African Nations

The analysis spans from 2024 (base year) to 2031 (forecast period).

Pre-Order / Enquiry Link: https://qyresearch.in/pre-order-inquiry/pharma-healthcare-mrna-vaccines-for-animals-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

Why This Report Is Essential -

✔ Complete Historical & Forecast Analysis (2020-2031)
✔ Detailed Segmentation by Type, Application & Region
✔ In-Depth Competitive Landscape & Company Profiling
✔ Drivers, Restraints & Market Dynamics Explained
✔ Expert Insights to Support Strategic Planning

Report Objectives -

✔ Measure the global mRNA Vaccines for Animals market size (value & volume).
✔ Accurately analyze market shares, consumption trends, and segment performance.
✔ Examine major market dynamics and industry-shaping forces.
✔ Identify and discuss key production, revenue, and sales trends.
✔ Profile top market players and evaluate their competitive strategies.
✔ Review manufacturing practices, pricing structures, and cost trends.
✔ Compare regional and national market performance across key geographies.
✔ Forecast segment-wise and region-wise growth opportunities through 2031.

Key Questions Answered in the Report -

✔ What is the size and estimated growth rate of the global and regional mRNA Vaccines for Animals market?
✔ Which countries are expected to display the strongest growth?
✔ Which region will dominate the market throughout the forecast period?
✔ What are the main factors driving or restraining market expansion?
✔ What technological advancements are shaping future demand?
✔ Where are the key opportunities for new entrants and established players?
✔ Which companies currently hold the highest market share?
✔ How will market dynamics evolve from 2025 to 2031?

Table of Contents - Major Key Points:

1 Market Overview
1.1 mRNA Vaccines for Animals Product Introduction
1.2 Global mRNA Vaccines for Animals Market Size Forecast (2020-2031)
1.3 mRNA Vaccines for Animals Market Trends & Drivers
1.3.1 mRNA Vaccines for Animals Industry Trends
1.3.2 mRNA Vaccines for Animals Market Drivers & Opportunity
1.3.3 mRNA Vaccines for Animals Market Challenges
1.3.4 mRNA Vaccines for Animals Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global mRNA Vaccines for Animals Players Revenue Ranking (2024)
2.2 Global mRNA Vaccines for Animals Revenue by Company (2020-2025)
2.3 Key Companies mRNA Vaccines for Animals Manufacturing Base Distribution and Headquarters
2.4 Key Companies mRNA Vaccines for Animals Product Offered
2.5 Key Companies Time to Begin Mass Production of mRNA Vaccines for Animals
2.6 mRNA Vaccines for Animals Market Competitive Analysis
2.6.1 mRNA Vaccines for Animals Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by mRNA Vaccines for Animals Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in mRNA Vaccines for Animals as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Non-replicating mRNA vaccines
3.1.2 Self-replicating mRNA vaccines
3.2 Global mRNA Vaccines for Animals Sales Value by Type
3.2.1 Global mRNA Vaccines for Animals Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global mRNA Vaccines for Animals Sales Value, by Type (2020-2031)
3.2.3 Global mRNA Vaccines for Animals Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Pigs
4.1.2 Poultry
4.1.3 Companion Animals
4.1.4 Ruminants
4.2 Global mRNA Vaccines for Animals Sales Value by Application
4.2.1 Global mRNA Vaccines for Animals Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global mRNA Vaccines for Animals Sales Value, by Application (2020-2031)
4.2.3 Global mRNA Vaccines for Animals Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global mRNA Vaccines for Animals Sales Value by Region
5.1.1 Global mRNA Vaccines for Animals Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global mRNA Vaccines for Animals Sales Value by Region (2020-2025)
5.1.3 Global mRNA Vaccines for Animals Sales Value by Region (2026-2031)
5.1.4 Global mRNA Vaccines for Animals Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America mRNA Vaccines for Animals Sales Value, 2020-2031
5.2.2 North America mRNA Vaccines for Animals Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe mRNA Vaccines for Animals Sales Value, 2020-2031
5.3.2 Europe mRNA Vaccines for Animals Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific mRNA Vaccines for Animals Sales Value, 2020-2031
5.4.2 Asia Pacific mRNA Vaccines for Animals Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America mRNA Vaccines for Animals Sales Value, 2020-2031
5.5.2 South America mRNA Vaccines for Animals Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa mRNA Vaccines for Animals Sales Value, 2020-2031
5.6.2 Middle East & Africa mRNA Vaccines for Animals Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions mRNA Vaccines for Animals Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions mRNA Vaccines for Animals Sales Value, 2020-2031
6.3 United States
6.3.1 United States mRNA Vaccines for Animals Sales Value, 2020-2031
6.3.2 United States mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
6.3.3 United States mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe mRNA Vaccines for Animals Sales Value, 2020-2031
6.4.2 Europe mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China mRNA Vaccines for Animals Sales Value, 2020-2031
6.5.2 China mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
6.5.3 China mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan mRNA Vaccines for Animals Sales Value, 2020-2031
6.6.2 Japan mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea mRNA Vaccines for Animals Sales Value, 2020-2031
6.7.2 South Korea mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia mRNA Vaccines for Animals Sales Value, 2020-2031
6.8.2 Southeast Asia mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India mRNA Vaccines for Animals Sales Value, 2020-2031
6.9.2 India mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
6.9.3 India mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Ceva Animal Health
7.1.1 Ceva Animal Health Profile
7.1.2 Ceva Animal Health Main Business
7.1.3 Ceva Animal Health mRNA Vaccines for Animals Products, Services and Solutions
7.1.4 Ceva Animal Health mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
7.1.5 Ceva Animal Health Recent Developments
7.2 Merck Animal Health
7.2.1 Merck Animal Health Profile
7.2.2 Merck Animal Health Main Business
7.2.3 Merck Animal Health mRNA Vaccines for Animals Products, Services and Solutions
7.2.4 Merck Animal Health mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
7.2.5 Merck Animal Health Recent Developments
7.3 Areterna
7.3.1 Areterna Profile
7.3.2 Areterna Main Business
7.3.3 Areterna mRNA Vaccines for Animals Products, Services and Solutions
7.3.4 Areterna mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
7.3.5 Areterna Recent Developments
7.4 Bayer
7.4.1 Bayer Profile
7.4.2 Bayer Main Business
7.4.3 Bayer mRNA Vaccines for Animals Products, Services and Solutions
7.4.4 Bayer mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
7.4.5 Bayer Recent Developments
7.5 BioNTech
7.5.1 BioNTech Profile
7.5.2 BioNTech Main Business
7.5.3 BioNTech mRNA Vaccines for Animals Products, Services and Solutions
7.5.4 BioNTech mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
7.5.5 BioNTech Recent Developments
7.6 Genvax Technologies
7.6.1 Genvax Technologies Profile
7.6.2 Genvax Technologies Main Business
7.6.3 Genvax Technologies mRNA Vaccines for Animals Products, Services and Solutions
7.6.4 Genvax Technologies mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
7.6.5 Genvax Technologies Recent Developments
7.7 BioVenic
7.7.1 BioVenic Profile
7.7.2 BioVenic Main Business
7.7.3 BioVenic mRNA Vaccines for Animals Products, Services and Solutions
7.7.4 BioVenic mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
7.7.5 BioVenic Recent Developments
7.8 Moderna
7.8.1 Moderna Profile
7.8.2 Moderna Main Business
7.8.3 Moderna mRNA Vaccines for Animals Products, Services and Solutions
7.8.4 Moderna mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
7.8.5 Moderna Recent Developments
7.9 Ruipu Biotechnology
7.9.1 Ruipu Biotechnology Profile
7.9.2 Ruipu Biotechnology Main Business
7.9.3 Ruipu Biotechnology mRNA Vaccines for Animals Products, Services and Solutions
7.9.4 Ruipu Biotechnology mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
7.9.5 Ruipu Biotechnology Recent Developments
7.10 Jinyu Bio-technology
7.10.1 Jinyu Bio-technology Profile
7.10.2 Jinyu Bio-technology Main Business
7.10.3 Jinyu Bio-technology mRNA Vaccines for Animals Products, Services and Solutions
7.10.4 Jinyu Bio-technology mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
7.10.5 Jinyu Bio-technology Recent Developments
7.11 Shanghai Shen Lian Biomedical
7.11.1 Shanghai Shen Lian Biomedical Profile
7.11.2 Shanghai Shen Lian Biomedical Main Business
7.11.3 Shanghai Shen Lian Biomedical mRNA Vaccines for Animals Products, Services and Solutions
7.11.4 Shanghai Shen Lian Biomedical mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
7.11.5 Shanghai Shen Lian Biomedical Recent Developments
7.12 Suzhou Kerui Meide Biomedical Technology
7.12.1 Suzhou Kerui Meide Biomedical Technology Profile
7.12.2 Suzhou Kerui Meide Biomedical Technology Main Business
7.12.3 Suzhou Kerui Meide Biomedical Technology mRNA Vaccines for Animals Products, Services and Solutions
7.12.4 Suzhou Kerui Meide Biomedical Technology mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
7.12.5 Suzhou Kerui Meide Biomedical Technology Recent Developments
7.13 Shanghai Rnacure Biopharma
7.13.1 Shanghai Rnacure Biopharma Profile
7.13.2 Shanghai Rnacure Biopharma Main Business
7.13.3 Shanghai Rnacure Biopharma mRNA Vaccines for Animals Products, Services and Solutions
7.13.4 Shanghai Rnacure Biopharma mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
7.13.5 Shanghai Rnacure Biopharma Recent Developments
8 Industry Chain Analysis
8.1 mRNA Vaccines for Animals Industrial Chain
8.2 mRNA Vaccines for Animals Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 mRNA Vaccines for Animals Sales Model
8.5.2 Sales Channel
8.5.3 mRNA Vaccines for Animals Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

About Us:

QYResearch established as a research firm in 2007 and have since grown into a trusted brand amongst many industries. Over the years, we have consistently worked toward delivering high-quality customized solutions for wide range of clients ranging from ICT to healthcare industries. With over 50,000 satisfied clients, spread over 80 countries, we have sincerely strived to deliver the best analytics through exhaustive research methodologies.

Contact Us:

Arshad Shaha | Marketing Executive

QY Research, INC.
315 Work Avenue, Raheja Woods,
Survey No. 222/1, Plot No. 25, 6th Floor,
Kayani Nagar, Yervada, Pune 411006, Maharashtra
Tel: +91-8669986909
Emails - arshad@qyrindia.com
Web - https://www.qyresearch.in

This release was published on openPR.